Why the study?
Can Lp(a) be useful in risk assessment for cardiovascular disease?
Can Lp(a) be useful in risk assessment for cardiovascular disease?
Although a definitive causal role for Lp(a) in CHD remains unproven due to a lack of targeted intervention trials, Lp(a) analysis may be a useful tool for risk assessment in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Lp(a) testing may refine CHD risk assessment in high-risk patients; leaves open causality and therapeutic benefit pending intervention trials.
Marcovina et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: